ArticleArthritis research & therapy2019
Autologous hematopoietic stem cell transplantation in systemic sclerosis induces long-lasting changes in B cell homeostasis toward an anti-inflammatory B cell cytokine pattern.
Article in Arthritis research & therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 47 citations in OpenAlex.
- Myeloablation Followed by Hematopoietic Stem Cell Transplantation and Long-Term Normalization of Systemic Sclerosis Molecular Signatures.Arthritis & rheumatology (Hoboken, N.J.) · 2024Trial
- Long-Term Suppression of Circulating Proinflammatory Cytokines in Multiple Sclerosis Patients Following Autologous Haematopoietic Stem Cell Transplantation.Frontiers in immunology · 2021Trial
- Challenges and strategies in clinical applications of CAR-T therapy for autoimmune diseases.Journal of hematology & oncology · 2025Review
- Defining immune reset: achieving sustained remission in autoimmune diseases.Nature reviews. Immunology · 2025Review
- Clinical and immunological long-term outcomes after autologous hematopoietic stem cell transplantation in systemic sclerosis: a retrospective single-center experience.Therapeutic advances in musculoskeletal disease · 2025Article
- Regulatory B Cells Contribute to the Clinical Response After Bone Marrow-Derived Mesenchymal Stromal Cell Infusion in Patients With Systemic Sclerosis.Stem cells translational medicine · 2023Article
- Myeloablative autologous haematopoietic stem cell transplantation resets the B cell repertoire to a more naïve state in patients with systemic sclerosis.Annals of the rheumatic diseases · 2023Article
- Stem cell-based therapy for systemic sclerosis.Rheumatology advances in practice · 2023Review
- Review
- Immune cell dysregulation as a mediator of fibrosis in systemic sclerosis.Nature reviews. Rheumatology · 2022Review
- B-Cell Reconstitution After Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis.Neurology(R) neuroimmunology & neuroinflammation · 2022Article
- Autoantibodies as Biomarker and Therapeutic Target in Systemic Sclerosis.Biomedicines · 2022Review
- Lymphocyte subsets in the peripheral blood are disturbed in systemic sclerosis patients and can be changed by immunosuppressive medication.Rheumatology international · 2022Article
- The Role of B Cells in Scleroderma Lung Disease Pathogenesis.Frontiers in medicine · 2022Review
- Role of B-Cell in the Pathogenesis of Systemic Sclerosis.Frontiers in immunology · 2022Review
- Reconstitution of the immune system and clinical correlates after stem cell transplantation for systemic sclerosis.Frontiers in immunology · 2022Review
- Dysregulated B cell function and disease pathogenesis in systemic sclerosis.Frontiers in immunology · 2022Review
- New autoimmune diseases after autologous hematopoietic stem cell transplantation for multiple sclerosis.Bone marrow transplantation · 2021Review
- B cells in systemic sclerosis: from pathophysiology to treatment.Clinical rheumatology · 2021Review
- Systemic sclerosis (scleroderma): remaining challenges.Annals of translational medicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
backgroundAutologous hematopoietic stem cell transplantation (aHSCT) is performed in patients with aggressive forms of systemic sclerosis (SSc). The profile of B cell reconstitution after aHSCT is not fully understood. The aim of this study was to investigate changes of B cell subsets and cytokine production of B cells in patients with SSc after aHSCT.
methodsPeripheral blood of six patients with SSc was collected at defined intervals up to 16 months after aHSCT. Immunophenotyping was performed, and B cell function was determined by measuring cytokine secretion in supernatants of stimulated B cell cultures.
resultsWithin 1 month after aHSCT, a peak in the percentage of CD38
conclusionA changed composition of the B cell compartment is present for up to 14 months after aHSCT indicating positive persisting effects of aHSCT on B cell homeostasis. The cytokine secretion profile of B cells changes in the long term and shows an increased production of the immune regulatory cytokine IL-10 after aHSCT. These findings might promote the clinical improvements after aHSCT in SSc patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.